BTN3A2 and central nervous system cancer: Collectively, these findings establish BTN3A2 as a hypoxia-driven, cell-intrinsic mediator of glioma progression and chemoresistance, highlighting its potential value as a prognostic biomarker and therapeutic vulnerability.